Merck & Co Inc
MRK: XNYS (USA)
| Morningstar Rating for Stocks | Fair Value | Economic Moat | Capital Allocation |
|---|---|---|---|
| PLG | LOCK|n! | LOCK|N@^!f& |
Merck Earnings: Modest 2027 Expectations, but Growing Pipeline Potential
Merck’s third-quarter sales grew 5%, while non-GAAP EPS fell 3%. Management nudged up the low end of 2026 revenue guidance, now implying 3%-4% revenue growth, and raised non-GAAP EPS guidance to a range of $2.77-$2.82. Shares rose 4% on Oct. 29.
